Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs MIRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Captures Overall Composite Edge (44.7 HOLD vs 38.1 SELL), While MIRM Leads 4–1 on Growth & Valuation Pillars

CRSP Overall Winner 6-Pillar Tally: CRSP 1 – 4 MIRM (1 Tie) Matrix Metrics: CRSP 6 – 4 MIRM

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Mirum Pharmaceuticals, Inc. (MIRM) on higher Unified Composite conviction (44.7/100 HOLD vs. 38.1/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples), while MIRM wins 4–1 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus MIRM at $92.92 (N/M Forward P/E, -21.6% operating margin).

  • Growth vs. Quality Trade-Off: CRSP earns the overall head-to-head edge with a stronger Unified Composite Score (44.7/100 HOLD vs. MIRM 38.1/100 SELL) and 1.85β · 60% Vol risk profile, whereas MIRM leads top-line expansion (+39.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile MIRM is in a Breakdown options structure phase (RSI 57.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs MIRM
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79
MIRM NASDAQ
Mirum Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$92.92
-1.14% 1D
Market Cap $6.1B
TTM Revenue $671M
Forward P/E N/M
Beta / 30D Vol 1.02β · 49% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 8.0 Fund 37.0 Flow 71.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.4 · SMA20: $88.87 · SMA50: $88.63

6-Pillar Scorecard Institutional Category Breakdown (CRSP 1 – 4 MIRM)

Columns: Metric · CRSP · MIRM
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.8x
2. Growth & Scale MIRM
Revenue Growth (YoY) +1325.1% +39.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $671M
Market Cap $4.1B $6.1B
3. Profitability & Quality MIRM
Gross Margin N/A 81.7%
Operating Margin -2058.6% -21.6%
Net Profit Margin 0.0% -134.8%
Return on Equity (ROE) -25.6% -760.0%
4. Balance Sheet & Cash Flow MIRM
Cash Generation (TTM) -$378M -$309M
Cash Flow Margin N/A -46.0%
Net Cash / Leverage $588M Net Debt (0.47x D/E) $500M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MIRM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 97.8% (52nd %ile) 72.6% (9th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (6) vs MIRM (4)
Institutional Metric CRSP MIRM Criterion Row Edge
Market Capitalization
Scale
$4.1B $6.1B Larger Scale MIRM
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% +39.6% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -21.6% Higher Margin MIRM
Net Profit Margin
Profitability
0.0% -134.8% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-25.6% -760.0% Higher ROE CRSP
52-Week Range Position
Momentum
1% ($40–$63) 44% ($63–$130) Stronger Trend MIRM
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 1.02β · 49% Vol Lower Realized Risk MIRM
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $671M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$309M ($500M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MIRM +33.48 pp
CRSP: -17.54% · MIRM: +15.94%
3M Horizon MIRM +15.44 pp
CRSP: -23.33% · MIRM: -7.89%
6M Horizon MIRM +13.67 pp
CRSP: -16.37% · MIRM: -2.7%
1Y Horizon MIRM +54.71 pp
CRSP: -20.54% · MIRM: +34.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue MIRM Revenue CRSP Op. Margin MIRM Op. Margin Margin Leader
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M N/A 16.1% N/A CRSP
FY2020 $0M N/A -49295.5% N/A CRSP
FY2021 $910M $20M 40.8% -906.1% CRSP
FY2022 $0M $80M -56190.4% -170.3% MIRM
FY2023 $370M $190M -60.0% -58.6% MIRM
FY2024 $40M $340M -1250.4% -26.0% MIRM
FY2025 $0M $520M -18933.6% -4.2% MIRM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MIRM BREAKDOWN
92d in phase · OBV NEUTRAL
Current IV 72.6%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MIRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MIRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1B market capitalization and -21.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs MIRM Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) captures the overall head-to-head institutional edge over Mirum Pharmaceuticals, Inc. (MIRM) on higher Unified Composite conviction (44.7/100 HOLD vs. 38.1/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples), while MIRM wins 4–1 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus MIRM at $92.92 (N/M Forward P/E, -21.6% operating margin). Growth vs. Quality Trade-Off: CRSP earns the overall head-to-head edge with a stronger Unified Composite Score (44.7/100 HOLD vs. MIRM 38.1/100 SELL) and 1.85β · 60% Vol risk profile, whereas MIRM leads top-line expansion (+39.6% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile MIRM is in a Breakdown options structure phase (RSI 57.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MIRM leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with MIRM at +39.6% YoY revenue growth and +0.0% YoY earnings growth on $671M TTM revenue (81.7% gross margin, -21.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while MIRM shifted +2500.0%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MIRM.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MIRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (-46.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus MIRM (-760.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, MIRM carries 72.6% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.